MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program
29-Jun-2010 -
MorphoSys AG and Xencor, Inc. announced the signing of a worldwide exclusive license and collaboration agreement for an antibody in Phase 1 clinical development. The agreement provides MorphoSys with an exclusive worldwide license to XmAb5574, a high potency monoclonal antibody developed by ...
acute lymphoblastic leukemia
antibodies
chronic lymphocytic leukemia
+3